Society of Urologic Oncology - MANAGEMENT AND OUTCOMES OF PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR UROTHELIAL CARCINOMA OF THE BLADDER: EVOLUTION OF THE UNIVERSITY OF SOUTHERN CALIFORNIA EXPERIENCE OVER 3,347 CASES
The overall survival did not reach median. The median progression free... | Download Scientific Diagram
The Treatment Landscape of Metastatic Urothelial Carcinoma: Second-Line Systemic Therapy
Survival Analysis in R
A retrospective analysis of changes in distant and breast cancer related disease-free survival events in adjuvant breast cancer trials over time | Scientific Reports
Median overall survival (mOS) and median progression-free survival... | Download Scientific Diagram
Novartis announces NEJM publication of updated analysis from ELIANA trial showing longer-term durable remissions with Kymriah(TM) in children, young adults with r/r ALL
Survival Analysis in R
Survival Analysis in R
Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study | British Journal of Cancer
Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors | Scientific Reports
Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer
Survival curves. (A) Overall survival (median 18.2 months). (B) PS of... | Download Scientific Diagram
How Median Follow-up Time Informs Survival Outcomes: Lessons from a Trial of Acute Myeloid Patients Treated with Venetoclax and Azacitidine - ScienceDirect
Opdualag™ (nivolumab and relatlimab-rmbw) Efficacy in Melanoma
Let's Flip: An Approach to Understand Median Follow-up by the Reverse Kaplan-Meier Estimator from a Statistical Programmer's
TIBSOVO® (ivosidenib tablets) an IDH1 Inhibitor
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer | NEJM
Survival Analysis
Example Kaplan-Meier (KM) curves of overall survival (OS) from an... | Download Scientific Diagram
Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry - The Lancet Regional Health – Europe
GraphPad Prism 10 Statistics Guide - Determining the median followup time
Kaplan-Meier survival analysis
Overall survival for suPAR levels above or below a 12 ng/mL cutoff.... | Download Scientific Diagram
